Double-blind, double-dummy comparison between treatment andwith rifaximin and lactulose in patients with medium to severe patients with medium to severe
The DOI matches its Crossref record.
Abstract
Fifty-eight patients, 30 males and 28 females, aged between 42 and 60 years (mean age 57 years) suffering from cirrhosis of the liver with signs and symptoms of portosystemic encephalopathy were studied. The double-blind study was performed according to a double-dummy experimental design, comparing the antibiotic rifaximin, administered at a dose of 1200 mg/day, with lactulose, administered at a dose of 30 g/day, both for 15 days. At the end of the treatment with the two drugs, there was a significant improvement in the main symptoms of portosystemic encephalopathy (mental state, asterixis, 'A' cancellation test, Reitan test). The improvement, which was also confirmed by a reduction in the overall score attributed to the degree of portosystemic encephalopathy was undoubtedly correlated with the reduction in the levels of serum ammonia concentrations, recorded after only 3 days of treatment. Tolerability of the treatment with rifaximin was decidedly higher with respect to lactulose. The greater rapidity of action and the lack of side-effects with rifaximin recommend the use of this intestinal antibiotic in patients with medium to severe portosystemic encephalopathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rifaximin Treatment in Hepatic Encephalopathy
Bass, N. M., Mullen, K. D., Sanyal, A., Poordad, F., Neff, G., Leevy, C. B., Sigal, S., Sheikh, M. Y., Beavers, K., Frederick, T., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907893 · Cited by 1,300
Treatment of Hepatic Encephalopathy
Riordan, S. M., & Williams, R. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708143370707 · Cited by 489
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
Rose, C. F., Amodio, P., Bajaj, J. S., Dhiman, R. K., Montagnese, S., Taylor-Robinson, S. D., Vilstrup, H., & Jalan, R. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.07.013 · Cited by 470
Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials
Als-Nielsen, B., Gluud, L. L., & Gluud, C. (2004) · BMJ · doi:10.1136/bmj.38048.506134.ee · Cited by 371
Sharma, B. C., Sharma, P., Lunia, M. K., Srivastava, S., Goyal, R., & Sarin, S. K. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.219 · Cited by 343
Metadata
- Authors
- Bucci, L., & Palmieri, G. C.
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa Healthcare
- Published
- 1993-01
- Volume
- 13
- Issue
- 2
- Pages
- 109-118
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2025778359
- Cited by
- 131
- References
- 0
- FWCI
- 0.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Double-blind, double-dummy comparison between treatment andwith rifaximin and lactulose in patients with medium to severe patients with medium to severe. https://app.cochat.ai/papers/10.1185/03007999309111539
- The paper
- Bucci, L., & Palmieri, G. C. (1993). Double-blind, double-dummy comparison between treatment andwith rifaximin and lactulose in patients with medium to severe patients with medium to severe. Current Medical Research and Opinion. https://doi.org/10.1185/03007999309111539
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.